Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05438420
Title Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Qurient Co., Ltd.
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.